行情

TEVA

TEVA

梯瓦制药
NYSE

实时行情|Nasdaq Last Sale

8.95
-0.10
-1.11%
盘后: 8.97 +0.02 +0.22% 19:48 09/24 EDT
开盘
8.95
昨收
9.05
最高
9.05
最低
8.90
成交量
541.43万
成交额
--
52周最高
13.30
52周最低
8.24
市值
98.66亿
市盈率(TTM)
-2.5036
分时
5日
1月
3月
1年
5年
生长激素缺乏症市场:2028 年增长、新兴趋势和预测的行业洞察
Research Nester published a report titled  which delivers a detailed overview of the growth hormone deficiency market in terms of market segmentation by application, by route of administration, by distribution channel,  and by region.
AmericaNewsHour · 2天前
2021 年生物仿制药市场报告:增加投资、产品发布和合作以刺激增长——预测到 2026 年
The is expected to exceed more than US$ 23.50 Billion by 2024 at a CAGR of 31% in the given forecast period.
Heraldkeepers · 5天前
全球骨髓增殖性疾病 (MPD) 治疗市场——研究行业规模、主要参与者的全球业务状况、需求增长的份额分析、到 2021-2029 年的毛利率分析预测
Research Nester released a report titled which delivers a detailed overview of the global myeloproliferative disorder treatment market in terms of market segmentation by type, treatment, end-user, and by region.
AmericaNewsHour · 5天前
根据大卫艾布拉姆斯的说法,今天投资的 15 只最佳股票
In this article, we discuss the 15 best stocks to invest in today according to David Abrams based on Q2 holdings of the fund. If you want to skip our detailed analysis of Abrams’ history, investment philosophy, and hedge fund performance, go directly to th...
Insider Monkey · 6天前
甲氨蝶呤药物市场-关键商机、令人印象深刻的增长率和到 2028 年的发展分析
Research Nester published a report titled  which delivers a detailed overview of the Methotrexate  Drug market in terms of market segmentation by type, by route of administration, by application, by end-users, by distribution channel, and region.
AmericaNewsHour · 6天前
由于到 2029 年个人骨髓增生性疾病的患病率不断上升,全球骨髓增生性疾病 (MPD) 治疗市场将增长
Research Nester released a report titled which delivers a detailed overview of the global myeloproliferative disorder treatment market in terms of market segmentation by type, treatment, end-user, and by region.
AmericaNewsHour · 6天前
生长激素缺乏症市场:公司简介、增长战略、开发技术、机会和到 2028 年按地区的预测
Research Nester published a report titled  which delivers a detailed overview of the growth hormone deficiency market in terms of market segmentation by application, by route of administration, by distribution channel,  and by region.
AmericaNewsHour · 6天前
Teva (NYSE:TEVA) 的交易价格仍低于内在价值的可能原因
Teva Pharmaceutical Industries Limited (NYSE:TEVA) seems to be undervalued on a fundamental basis. However, sometimes stocks are trading below intrinsic value because there are factors external to the current money making capacity of the company. We will e...
Simply Wall St. · 09/17 09:05
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解TEVA最新的财务预测,通过TEVA每股收益,每股净资产,每股现金流等数据分析梯瓦制药近期的经营情况,然后做出明智的投资选择。
分析师评级

19位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测TEVA价格均价为11.47,最高价位14.00,最低价为10.00。
EPS
机构持股
总机构数: 700
机构持股: 5.98亿
持股比例: 54.24%
总股本: 11.02亿
类型机构数股数
增持
125
2,732.35万
建仓
41
298.96万
减持
136
3,636.48万
平仓
46
566.48万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-0.45%
制药与医学研究
-1.02%
高管信息
Non-Executive Chairman/Independent Director
Sol Barer
President/Chief Executive Officer/Director
Kaare Schultz
Chief Financial Officer/Executive Vice President
Eliyahu Kalif
Chief Human Resource Officer/Executive Vice President
Galia Inbar
Executive Vice President
Richard Daniell
Executive Vice President
Sven Dethlefs
Executive Vice President
Eric Drape
Executive Vice President
Hafrun Fridriksdottir
Executive Vice President
Mark Sabag
Executive Vice President
Eli Shani
Executive Vice President
David Stark
Chief Accounting Officer
Andrew Weil
Independent Director
Rosemary Crane
Independent Director
Amir Elstein
Independent Director
Jean-Michel Halfon
Independent Director
Gerald Lieberman
Independent Director
Roberto Mignone
Independent Director
Perry Nisen
Independent Director
Nechemia Peres
Independent Director
Ronit Satchi-Fainaro
Independent Director
Janet Vergis
公告日期
每股分红
除权日期
--
每股分红:USD 0.072
2017/11/27
2017/08/04
每股分红:USD 0.072
2017/08/25
2017/05/16
每股分红:USD 0.289
2017/06/01
2017/03/16
每股分红:USD 0.289
2017/02/28
2016/11/17
每股分红:USD 0.289
2016/12/01
2016/08/08
每股分红:USD 0.289
2016/08/18
2016/05/11
每股分红:USD 0.289
2016/05/20
2016/02/16
每股分红:USD 0.289
2016/02/25
2015/11/02
每股分红:USD 0.289
2015/11/13
2015/07/31
每股分红:USD 0.289
2015/08/18
2015/05/05
每股分红:USD 0.289
2015/05/15
2015/02/20
每股分红:USD 0.294
2015/02/17
2014/11/18
每股分红:USD 0.27
2014/11/13
2014/08/25
每股分红:USD 0.291
2014/08/19
2014/05/20
每股分红:USD 0.298
2014/05/16
2014/03/05
每股分红:USD 0.293
2014/02/20
2013/11/21
每股分红:USD 0.278
2013/11/18
2013/08/21
每股分红:USD 0.274
2013/08/16
  • 全部
  • 财务报告
  • 内部人交易
更多
TEVA 简况
Teva Pharmaceutical Industries Ltd是一家以色列制药公司。该公司运营三个分部:北美、欧洲和国际市场。每个业务部门管理其所在区域的的所有产品组合,包括仿制药、专利药和非处方(OTC)药产品。除了其三个分部外,该公司还从事其他活动,主要包括向第三方销售活性药物成分(API)、特定合同的制造服务、以及通过其附属公司Medis向其他制药公司提供产品组合的对外许可平台。

微牛提供Teva Pharmaceutical Industries Ltd (ADR)(NYSE-TEVA)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的TEVA股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易TEVA股票基本功能。